Prevention and elimination of bovine viral diarrhea virus infections in fetal fibroblast cells.

Noncytopathic infections with bovine viral diarrhea virus (BVDV) can compromise research and commercial use of cultured cells. The purpose of this research was to evaluate the ability of aromatic cationic compounds to prevent or treat BVDV infections in fetal fibroblast cell lines that are used in somatic cell nuclear transfer. To evaluate preventative use of compounds, 10 cell lines were inoculated with BVDV in the absence or presence of 2-(4-[2-imidazolinyl]phenyl)-5-(4-methoxyphenyl)furan (DB606), 2-(2-benzimidazolyl)-5-[4-(2-imidazolino)phenyl]furan dihydrochloride (DB772), or 2-(1-methyl-2-benzimidazolyl)-5-[4'-(2-imidazolino)-2'-methylphenyl]furan dihydrochloride (DB824). The 99% endpoints for prevention of viral replication by these treatments were 81, 6, and 14 nM. To evaluate therapeutic use of compounds, two fetal fibroblast cell lines infected with a genotype 1a strain of BVDV were cultured through four passages in the absence or presence of either 0.04 or 4 microM concentrations of DB772 or DB824. The presence and concentration of BVDV in media and cell lysates were evaluated using reverse transcription nested polymerase chain reaction and virus isolation from titrated sample. A single passage in 4 microM of either compound was sufficient to eliminate BVDV from cells without causing cytotoxicity. Our results demonstrate that in vitro infections with BVDV can be effectively prevented or eliminated by addition of aromatic cations.